ALKERMES | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
ALKERMES USD 2.06B 99.72M 2024-12
Amgen USD 91.84B 956M 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Gilead Sciences USD 59B 4.47B 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
J&J USD 180.1B 1.82B 2024-12
Malin Corporation EUR 128.4M 11.8M 2024-06
Merck USD 117.11B 426M 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Otsuka Holdings JPY 3.74T 141.45B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



ALKERMES Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.